Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the treatment of glioblastoma. Vortioxetine, an antidepressant, showed promising anti-glioblastoma activity, significantly reducing tumor size in preclinical trials.
BMS receives FDA approval for Opdivo to treat NSCLC
BMS’ Opdivo is said to be the only PD-1 inhibitor to demonstrate an advantage over chemotherapy, both presurgery and in a perioperative setting. Credit: HJBC